

Supplemental Appendix

Supplemental Table 1

Kaplan Meier survival probabilities with 95% confidence intervals at 1 year and 5-years post admission x diagnostic group

		Outcome			
Diagnostic Group	Time	Death	MACE	MAKE	MARCE
AKI	1 year	0.70 (0.69-0.71)	0.93 (0.92-0.93)	0.61 (0.60-0.62)	0.56 (0.55-0.57)
MI	1 year	0.86 (0.86-0.87)	0.81 (0.81-0.82)	0.84 (0.83-0.84)	0.69 (0.68-0.70)
MI+AKI	1 year	0.66 (0.65-0.67)	0.75 (0.74-0.76)	0.58 (0.57-0.59)	0.43 (0.42-0.44)
AKI	5 years	0.41 (0.39-0.42)	0.86 (0.85-0.87)	0.25 (0.23-0.27)	0.23 (0.21-0.24)
MI	5 years	0.66 (0.65-0.67)	0.72 (0.71-0.73)	0.51 (0.50-0.52)	0.40 (0.38-0.41)
MI+AKI	5 years	0.41 (0.40-0.43)	0.65 (0.64-0.67)	0.24 (0.22-0.25)	0.16 (0.15-0.18)

Supplemental Table 2

Sensitivity analysis I: Event analysis by Baseline eGFR Tertile

	Pre-admission eGFR	Log-Rank Chi-square (p)	Cox HR for AKI vs. MI (95% ci; p)	Cox HR for MI + AKI vs. MI (95% ci; p)
Death	<= 62	421.1 (p<.0001)	1.55 (1.44-1.66; p<.0001)	1.91 (1.78-2.05; p<.0001)
	63-79	754.3 (p<.0001)	2.05 (1.89-2.22; p<.0001)	2.25 (2.10-2.42; p<.0001)
	>79	678.8 (p<.0001)	2.07 (1.88-2.27; p<.0001)	2.20 (2.03-2.38; p<.0001)
MACE	<= 62	348.3 (p<.0001)	0.48 (.43-.53; p<.0001)	1.20 (1.10-1.30; p<.0001)
	63-79	337.6 (p<.0001)	0.38 (.33-.43; p<.0001)	1.24 (1.14-1.34; p<.0001)
	>79	322.0 (p<.0001)	0.27 (.22-.33; p<.0001)	1.32 (1.21-1.44; p<.0001)
MAKE	<= 62	710.0 (p<.0001)	1.73 (1.62-1.84; p<.0001)	2.11 (1.98-2.24; p<.0001)
	63-79	1185.8 (p<.0001)	2.22 (2.07-2.39; p<.0001)	2.35 (2.21-2.50; p<.0001)
	>79	1195.7 (p<.0001)	2.39 (2.21-2.58; p<.0001)	2.35 (2.19-2.51; p<.0001)
MARCE	<= 62	558.4 (p<.0001)	1.23 (1.16-1.31; p<.0001)	1.80 (1.70-1.90; p<.0001)
	63-79	816.2 (p<.0001)	1.42 (1.33-1.51; p<.0001)	1.96 (1.86-2.08; p<.0001)
	>79	754.8 (p<.0001)	1.47 (1.37-1.58; p<.0001)	1.96 (1.85-2.08; p<.0001)

Legend: Cox Survival Analysis adjusted for Age, Gender, African American race, history of CAD, previous CVA, serum albumin < 3 g/dL, DM, HTN, and baseline eGFR.

Supplemental Table 3

Outcomes by Diagnostic Group and Severity of AKI

	n	CVA	rMI	CHF	eGFR drops 25%	HD	Death	MACE + Death	MAKE	MARCE
AKI (p)		.04	.012	<.0001	<.0001	.003	.25	.55	<.0001	<.0001
I	1958	33 (1.7%)	51 (2.6%)	181 (9.2%)	536 (27.4%)	4 (0.2%)	1012 (51.7%)	1095 (55.9%)	951 (48.6%)	1042 (53.2%)
II	2338	36 (1.5%)	53 (2.3%)	244 (10.4%)	743 (31.8%)	9 (0.4%)	1233 (52.7%)	1339 (57.3%)	1233 (52.7%)	1342 (57.4%)
III	4130	41 (1.0%)	64 (1.6%)	222 (5.4%)	1665 (40.3%)	35 (0.9%)	2226 (53.9%)	2311 (56.0%)	2372 (57.4%)	2464 (59.7%)
MI+AKI (p)		.10	<.0001	.009	<.0001	.052	<.0001	<.0001	<.0001	<.0001
I	7561	173 (2.3%)	1452 (19.2%)	1126 (14.9%)	2727 (36.1%)	8 (0.1%)	4048 (53.5%)	5023 (66.4%)	4374 (57.9%)	5221 (69.1%)
II	1385	25 (1.8%)	204 (14.7%)	197 (14.2%)	735 (53.1%)	1 (0.1%)	972 (70.2%)	1072 (77.4%)	1020 (73.7%)	1114 (80.4%)
III	687	8 (1.2%)	65 (9.5%)	73 (10.6%)	441 (64.2%)	3 (0.4%)	517 (75.3%)	558 (81.2%)	544 (79.2%)	576 (83.8%)
MI	18921	385 (2.0%)	3081 (16.3%)	1433 (7.6%)	2584 (13.7%)	13 (0.07%)	6102 (32.3%)	8576 (45.3%)	6031 (31.9%)	8534 (45.1%)

CVA = Cerebrovascular Accident, MI = myocardial infarction cohort, rMI = repeat myocardial infarction, CHF = Congestive Heart Failure, HD = chronic hemodialysis, MACE = Major Adverse Cardiac Events, which includes stroke, congestive heart failure, or MI admission. MAKE = Major Adverse Kidney Events, which include death, dialysis, or eGFR decrease of 25% from mean baseline level. MARCE = Major Adverse Renal or Cardiac Events, which includes MACE or MAKE. I = KDIGO Stage I, II = KDIGO Stage II. and III = KDIGO Stage III.